	US 12,064,477 B2
	HPV vaccine
Lucy Dorrell, Oxford (GB); Joshua Blight, Oxford (GB); and Arturo Reyes-Sandoval, Oxford (GB)
Assigned to OXFORD UNIVERSITY INNOVATION LIMITED, Oxford (GB)
Filed by Oxford University Innovation Limited, Oxford (GB)
Filed on Nov. 22, 2021, as Appl. No. 17/532,177.
Application 17/532,177 is a continuation of application No. 16/639,144, granted, now 11,179,456, issued on Nov. 23, 2021, previously published as PCT/GB2018/052335, filed on Aug. 16, 2018.
Claims priority of application No. 1713163 (GB), filed on Aug. 16, 2017.
Prior Publication US 2022/0152189 A1, May 19, 2022
Int. Cl. A61K 39/12 (2006.01); A61K 39/39 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01)

CPC A61K 39/12 (2013.01) [A61K 39/39 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C07K 2319/00 (2013.01); C12N 2710/20022 (2013.01); C12N 2710/20034 (2013.01)]

11 Claims

1. A vaccine comprising a nucleic acid encoding a polypeptide comprising a plurality of conserved peptide sequences:

wherein the conserved sequences are conserved across one or more HPV genotypes 16, 18, 31, 52, 53, and 58;

wherein the polypeptide comprises a conserved peptide sequence of each of the HPV proteins E1, E2, E4, E5, E6, and E7; and further wherein

the nucleic acid comprises or consists of the sequence of SEQ ID NO: 60 or 62, with a different peptide adjuvant encoded than the TPA lead sequence; or

the nucleic acid comprises or consists of the sequence of SEQ ID NO: 71, 73 or 75, not encoding the TPA lead sequence.